First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors

被引：0
|
作者：
Sandhu, S. K. [1 ,2 ,3 ,4 ,5 ,6 ]
Fong, P. C. [1 ,2 ,3 ,4 ,5 ,6 ]
Frentzas, S. [1 ,2 ,3 ,4 ,5 ,6 ]
Patnaik, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Papadopoulos, K. [1 ,2 ,3 ,4 ,5 ,6 ]
Tromp, B. [1 ,2 ,3 ,4 ,5 ,6 ]
Puchalski, T. [1 ,2 ,3 ,4 ,5 ,6 ]
Berns, B. [1 ,2 ,3 ,4 ,5 ,6 ]
Tolcher, A. W. [1 ,2 ,3 ,4 ,5 ,6 ]
De-Bono, J. S. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] START, San Antonio, TX USA
[3] Ortho Biotech, Oncol, London, England
[4] Ortho Biotech, Oncol, Res & Dev, London, England
[5] S Texas Accelerated Res Therapeut, San Antonio, TX USA
[6] Inst Canc Res, London SW3 6JB, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13500
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
    Shahneen K. Sandhu
    Kyri Papadopoulos
    Peter C. Fong
    Amita Patnaik
    Christina Messiou
    David Olmos
    George Wang
    Brenda J. Tromp
    Thomas A. Puchalski
    Frances Balkwill
    Birge Berns
    Shobha Seetharam
    Johann S. de Bono
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1041 - 1050
  • [2] A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
    Sandhu, Shahneen K.
    Papadopoulos, Kyri
    Fong, Peter C.
    Patnaik, Amita
    Messiou, Christina
    Olmos, David
    Wang, George
    Tromp, Brenda J.
    Puchalski, Thomas A.
    Balkwill, Frances
    Berns, Birge
    Seetharam, Shobha
    de Bono, Johann S.
    Tolcher, Anthony W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 1041 - 1050
  • [3] Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.
    Forster, M. D.
    Patnaik, A.
    Sandhu, S. K.
    Papadopoulos, K.
    Tromp, B. J.
    Messiou, C.
    Balkwill, F.
    Berns, B.
    De Bono, J. S.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNT0888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors
    Sandhu, Shahneen K.
    Fong, Peter C.
    Patnaik, Amita
    Papadopoulos, Kyri
    Messiou, Christina
    Hoare, Susan
    Olmos, David
    Tromp, Brenda J.
    Puchalski, Thomas A.
    Balkwill, Frances
    Berns, Birge
    Debono, Johann S.
    Tolcher, Anthony W.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [5] Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    Pienta, Kenneth J.
    Machiels, Jean-Pascal
    Schrijvers, Dirk
    Alekseev, Boris
    Shkolnik, Mikhail
    Crabb, Simon J.
    Li, Susan
    Seetharam, Shobha
    Puchalski, Thomas A.
    Takimoto, Chris
    Elsayed, Yusri
    Dawkins, Fitzroy
    de Bono, Johann S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 760 - 768
  • [6] Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    Kenneth J. Pienta
    Jean-Pascal Machiels
    Dirk Schrijvers
    Boris Alekseev
    Mikhail Shkolnik
    Simon J. Crabb
    Susan Li
    Shobha Seetharam
    Thomas A. Puchalski
    Chris Takimoto
    Yusri Elsayed
    Fitzroy Dawkins
    Johann S. de Bono
    Investigational New Drugs, 2013, 31 : 760 - 768
  • [7] First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
    Do, Khanh T.
    Chow, Laura Quan Man
    Reckamp, Karen
    Sanborn, Rachel E.
    Burris, Howard
    Robert, Francisco
    Camidge, D. Ross
    Steuer, Conor E.
    Strickler, John H.
    Weise, Amy
    Specht, Jennifer M.
    Gutierrez, Martin
    Haughney, Peter
    Hengel, Shawna
    Derleth, Christina Louise
    Yap, Timothy A.
    ONCOLOGIST, 2021, 26 (11): : 925 - +
  • [8] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
    Razak, Albiruni R. Abdul
    Mau-Soerensen, Morten
    Gabrail, Nashat Y.
    Gerecitano, John F.
    Shields, Anthony F.
    Unger, Thaddeus J.
    Saint-Martin, Jean R.
    Carlson, Robert
    Landesman, Yosef
    McCauley, Dilara
    Rashal, Tami
    Lassen, Ulrik
    Kim, Richard
    Stayner, Lee-Anne
    Mirza, Mansoor R.
    Kauffman, Michael
    Shacham, Sharon
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4142 - +
  • [9] First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas.
    Rixe, Olivier
    Morris, John Charles
    Puduvalli, Vinay K.
    Villano, John L.
    Wise-Draper, Trisha Michel
    Muller, Carolyn
    Johnson, Angela N.
    Wesolowski, Robert
    Qi, Xiaoyang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
    Diaz, Luis A., Jr.
    Coughlin, Christina M.
    Weil, Susan C.
    Fishel, Jean
    Gounder, Mrinal M.
    Lawrence, Susan
    Azad, Nilofer
    O'Shannessy, Daniel J.
    Grasso, Luigi
    Wustner, Jason
    Ebel, Wolfgang
    Carvajal, Richard D.
    CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1281 - 1288
12345